AIM ImmunoTech Inc. Common Stock (AIM)
Stock · AMEX · Health Care
$0.17as of 10/16/2026
Price chart
Active signals
AIM Signal Track Record
How signals performed across all stocks →What AIM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | 0.0% | 40% | September 25, 2026 |
| Volume Spike | 14 | -12.6% | 7% | September 1, 2026 |
| Bollinger Band Breakout | 12 | -17.8% | 17% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -16.2% | 0% | June 14, 2024 |
| Any 20-session window (baseline) | -8.3% | 26% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa)…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 19
- Website
- aimimmuno.com/
Fundamentals
- 1-day range
- $0.1661$0.174
- Market cap
- $7.51M
- P/E (trailing)
- —
- P/E (forward)
- -0.45
- EPS (trailing)
- $-3.93
- Dividend yield
- —
- Beta
- 1.35
- Avg. volume
- 4.77M
How AIM ImmunoTech Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
AIM ImmunoTech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- CRISCuris Inc. Common Stock$0.41▼ 19.61%Market cap $8.59MP/E —$0.5733$33.6
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
- VIVSVivoSim Labs Inc. Common Stock$0.16▼ 5.88%Market cap $5.53MP/E —$0.1495$3.4
- BCABBioAtla Inc. Common Stock$1.36▲ 4.62%Market cap $5.53MP/E —$1.07$71.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| CRIS Curis Inc. Common Stock | $8.59M | — | $0.41 | ▼ 19.61% | $0.5733$33.6 |
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.16 | ▼ 5.88% | $0.1495$3.4 |
| BCAB BioAtla Inc. Common Stock | $5.53M | — | $1.36 | ▲ 4.62% | $1.07$71.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdaysYahoo · 10/7/2026
- AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense PotentialYahoo · 10/5/2026
- AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline DataYahoo · 10/1/2026
- AIM ImmunoTech Says Overall Survival Analysis In Phase 2 Pancreatic Cancer Trial To Begin In Q3 2027; Reiterates Q1 2027 Topline Databenzinga · 9/30/2026
- AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner VideoYahoo · 9/30/2026
- AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ DaraxonrasibYahoo · 9/22/2026
Insider Activity
Insider Actions →- Thomas K. Equels · September 17, 2026 · Buy24.0K @ $0.208
- Thomas K. Equels · September 16, 2026 · Buy11.0K @ $0.21
- Thomas K. Equels · September 15, 2026 · Buy22.0K @ $0.221
- Thomas K. Equels · September 14, 2026 · Buy5.9K @ $0.219
Institutional Ownership
March 31, 2026
- Total shares held
- 153.2K
- Total value held
- $44.7K
- Institutional holders
- 16
- Unknown50.9K
- Unknown29.9K
- Unknown26.0K
- Unknown20.6K
- Unknown20.0K
- Unknown4.7K
- Unknown864
- Unknown132
- Unknown32
- Unknown30
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress
AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.
AIM ImmunoTech Highlights Ampligen Pancreatic Cancer Progress. AIM ImmunoTech is drawing attention to its Ampligen strategy for pancreatic cancer as the DURIPANC study moves toward topline data. The company also released a CEO video discussing how Ampligen could complement new treatments in this area. This news provides context for the stock's current position within its 52-week range.